To allow subjects who have completed Insys 030 extension study to continue to take Cannabidiol oral solution.

To allow subjects who have completed Insys 030 extension study (A multicenter, open-label, flexible dose study to assess the long-term safety of pharmaceutical Cannabidiol Oral Solution as an adjunctive treatment for pediatric subjects with a treatment-resistant seizure disorder who complete INS011-14-029 or Part A of INS011-15-054) to continue to take Cannabidiol oral solution.

Inclusion Criteria:

1. Completed the Insys 030 protocol
2. Compliant in drug study procedures
3. Non-pregnant females of child bearing age, willing to utilize a double-barrier method of birth control during treatment and for 30 days after treatment has ended

Exclusion Criteria:

1. Failure to follow study procedures in Insys 030
2. Pregnant females